RxDoctor Payments Data

Ajay Bhargava, MD

Pediatric Gastroenterology · Lawton, OKNPI 1174624845

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 70 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Gilead at 54.8% of the total. Reporting peaked in 2022 at $301 and has fallen 57.2% since, to $129 in 2024.

$1,216in general payments, 2019–2025

Across 70 payments — averaging $17.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$666
  • AbbVie$148
  • Daiichi Sankyo Inc.$77
  • Intercept Pharmaceuticals, Inc.$56
  • Pfizer$43
  • Nestle Healthcare Nutrition Inc.$36
  • plus $190 from 9 others

What the payments were for

  • Food & beverage$1,216100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,216 in reported general payments places this provider in the 70th percentile of 20 pediatric gastroenterology providers in Oklahoma.

See all pediatric gastroenterology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$58,330
Medicare patients
181
Services billed
709

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide27$20,827
Balsalazide Disodium17$1,795
Lansoprazole56$1,645
Colestipol Hcl22$1,533
Misoprostol27$1,306
Esomeprazole Magnesium36$870
Ondansetron OdtOndansetron26$756
Famotidine48$633
Sucralfate32$605
Lactulose35$520
ConstuloseLactulose37$439
Mercaptopurine12$378
Sulfasalazine16$358
Bethanechol Chloride21$323
Omeprazole36$303

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$148$20,82727 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 20 pediatric gastroenterology providers in Oklahoma.

Other pediatric gastroenterology in Lawton

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →